Abemaciclib in Patients with End-Stage Renal Disease and Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Report of 2 Cases

Cyclin4/6-dependent kinase inhibitors (CDKIs) plus hormonotherapy currently represent the standard golden treatment for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor-2-negative (her-2−) advanced breast carcinoma. Among CDKIs, abemaciclib is the most active. N...

Descripción completa

Detalles Bibliográficos
Autor principal: Gebbia, Vittorio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035949/
https://www.ncbi.nlm.nih.gov/pubmed/35529297
http://dx.doi.org/10.1159/000523856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035949/
https://www.ncbi.nlm.nih.gov/pubmed/35529297
http://dx.doi.org/10.1159/000523856

Ejemplares similares